Why Novavax Is Bouncing Back

AaronJe
2022-09-28

By Keith Speights

KEY POINTS

  • Novavax announced that it has made 1 million doses of COVID-19 vaccine Nuvaxovid available in the U.K.
  • The company is still awaiting U.K. authorization for its vaccine to be used as a booster.

1 million doses of the company's COVID-19 vaccine are now available in the U.K.

What happened

Shares of Novavax($Novavax(NVAX)$ )were bouncing back. The gain came after an analyst's downgrade caused the stock to plunge last week.

Novavax had good news to report on Tuesday, though. The company announced that it's made 1 million doses of COVID-19 vaccine Nuvaxovid available for use in the U.K.

So what

It's difficult to predict how much uptake Nuvaxovid will enjoy in the U.K. Novavax received Conditional Marketing Authorization (CMA) from the country's Medicines and Healthcare products Regulatory Agency (MHRA) in February 2022 for vaccination of adults ages 18 and older. The company picked up another authorization for adolescents ages 12 through 17 last month.

But more than 80% of adults in the U.K. have already received at least one dose of a COVID-19 vaccine. Around 75.5% of adults in the country are fully vaccinated. Perhaps some of the unvaccinated who didn't want messenger RNA vaccines could be interested in Novavax's protein-based vaccine, especially if there's a major surge in COVID-19 cases as winter approaches.

However, Nuvaxovid still isn't available in the U.K. as a booster. Novavax filed for expanded CMA of its vaccine as a booster in adults in June but is still awaiting a decision from MHRA.

Now what

Novavax really needs to secure authorizations in the U.K. and the U.S. for Nuvaxovid boosters. In the meantime, it's likely that thevaccine stockwill remain highly volatile.

Over the longer term, though, Novavax could have an opportunity to achieve greater success. The company should soon announce results from a late-stage study of its vaccine targeting the coronavirus omicron variant. It also plans to advance a combination COVID/flu vaccine candidate into late-stage testing in 2023.

Resource: the Motley Fool

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • LWayne
    2022-09-29
    LWayne
    bouncing back? 1day action is not because of the stock
  • GangKK
    2022-09-29
    GangKK
    [Call] [Call] [Call] [Call] [Call] [Call] [Call] [Call]
  • Damien Khoo
    2022-09-29
    Damien Khoo
    Dead cat bounce maybe
  • Xman0808
    2022-09-29
    Xman0808
    Good
  • Vincent1968
    2022-09-29
    Vincent1968
    bullshit
  • SinThong
    2022-09-29
    SinThong
    [得意]
Leave a comment
56
2